Royal Bank of Canada Acquires 209,060 Shares of Abbott Laboratories $ABT

Royal Bank of Canada raised its holdings in shares of Abbott Laboratories (NYSE:ABT) by 3.3% during the 1st quarter, HoldingsChannel.com reports. The firm owned 6,463,522 shares of the healthcare product maker’s stock after acquiring an additional 209,060 shares during the quarter. Royal Bank of Canada’s holdings in Abbott Laboratories were worth $663,610,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. MidAtlantic Capital Management Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $25,000. Purpose Unlimited Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in shares of Abbott Laboratories in the 4th quarter worth $26,000. Finally, Abound Financial LLC bought a new position in Abbott Laboratories in the 4th quarter worth $26,000. 75.18% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. Leerink Partners lowered their target price on shares of Abbott Laboratories from $119.00 to $106.00 and set a “market perform” rating on the stock in a report on Tuesday, April 21st. Barclays decreased their price target on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. JPMorgan Chase & Co. raised their price objective on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. The Goldman Sachs Group cut their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Finally, Sanford C. Bernstein reduced their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $118.17.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Quarterly beat and raised guidance support investor confidence. Abbott reported second-quarter earnings of $1.31 per share, above the $1.28 consensus estimate, while revenue rose 13% year over year to $12.59 billion. Management raised its fiscal 2026 EPS outlook to $5.45-$5.60 and expects third-quarter EPS of $1.38-$1.46. Strong demand for cancer diagnostics and medical devices helped offset concerns about procedure volumes. Abbott Raised Its Profit Forecast
• Positive Sentiment: Growth initiatives provide multiple expansion paths. Abbott is investing in diabetes care, oncology diagnostics and cardiovascular devices through new product launches and acquisitions, giving investors several potential sources of future sales growth. Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends
• Positive Sentiment: New colorectal cancer screening rights strengthen Abbott’s diagnostics portfolio. Abbott secured exclusive U.S. commercialization rights for Freenome’s FDA-cleared SimpleScreen blood-based colorectal cancer test. The product could broaden screening access, particularly among Americans overdue for testing, although commercial adoption will determine the financial impact. FDA Approves Freenome’s SimpleScreen CRC Test
• Neutral Sentiment: Analysts remain constructive but see limited valuation upside. UBS lowered its ABT price target from $135 to $125 while maintaining a Buy rating, implying meaningful upside from the referenced trading level. Another analysis noted that Abbott’s earnings setup has improved, but its elevated valuation could constrain returns. UBS Abbott Price Target Update
• Negative Sentiment: Guidance and litigation concerns remain overhangs. Despite the earnings beat and improved outlook, investors continue to monitor legal risks and whether projected growth will justify Abbott’s premium earnings multiple. Abbott Fell as Guidance and Litigation Concerns Overshadowed Growth

Abbott Laboratories Price Performance

NYSE:ABT opened at $107.34 on Wednesday. The firm has a market cap of $186.97 billion, a price-to-earnings ratio of 34.74, a PEG ratio of 2.02 and a beta of 0.61. The firm’s fifty day moving average is $92.32 and its two-hundred day moving average is $100.85. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.65% and a net margin of 11.65%.The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.